Peanut allergen-specific immune cells

Peanut allergen-specific immune cells are a specialized population of leukocytes that drive the IgE-mediated hypersensitivity response to peanut proteins, such as Ara h 1 and Ara h 2. This population primarily consists of pathogenic T helper 2 (Th2A) cells and allergen-specific B cells that produce IgE antibodies (Wambre et al., 2017) [1.1.3]. Th2A cells are a distinct subset of memory Th2 cells (CD4+ CRTH2+ CD161+ CD27-) found only in allergic individuals; they secrete pro-inflammatory cytokines like IL-4, IL-5, and IL-13 upon allergen exposure, which promotes B-cell class switching to IgE and the activation of effector cells like mast cells and basophils (NIH, 2018) [1.1.1]. Therapeutic strategies targeting these cells include oral immunotherapy (OIT), such as Palforzia, which aims to induce desensitization or clinical tolerance by depleting Th2A clones or inducing regulatory T cells (Tregs) (Science Translational Medicine, 2017) [1.1.4]. Biologics like omalizumab (anti-IgE) and dupilumab (anti-IL-4Rα) modulate the activity of these cells by neutralizing IgE or blocking cytokine signaling, respectively (Journal of Allergy and Clinical Immunology, 2018) [1.1.1]. Monitoring the frequency and phenotype of these allergen-specific cells serves as a critical biomarker for assessing the efficacy of allergy immunotherapies and predicting the risk of anaphylaxis (EurekAlert, 2017) [1.1.4].

Other names

Peanut-reactive T cellsPeanut-specific Th2 cellsTh2A cellsPeanut-specific B cellsPeanut-specific IgE-producing cellsAllergen-specific lymphocytes

Allergen-specific desensitization; IgE neutralization; IL-4/IL-13 signaling inhibition; T-cell anergy induction; Regulatory T-cell (Treg) expansion; TSLP signaling blockade